Immuron Limited ADR Dossier - Source-backed chat

Immuron Limited ADR

IMCAustralian Securities Exchange

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.68

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.13Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $9.1M

Enterprise Value $6.4M

Shares Outstanding 8.1M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Immuron Ltd is transitioning from a conceptual biotechnology firm into a commercial-stage biopharmaceutical company, supported by its versatile hyperimmune bovine colostrum platform. The company's commercial portfolio, led by Travelan® and supplemented by the newly launched ProIBS®, provides a growing revenue stream that partially offsets its clinical development costs. With a strategic reset focused on securing partnerships to fund its high-value clinical assets (IMM-124E and IMM-529), Immuron offers an attractive risk-reward profile. The recent FDA approval of the IND application for IMM-529 paves the way for Phase 2 trials in recurrent C. difficile infections, representing a major valuation catalyst.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.90

Mean target$3.90

High · most bullish analyst$3.90

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case involves a failure to secure strategic partnerships, forcing the company to rely heavily on its At-The-Market (ATM) facility or dilutive equity raises to fund expensive Phase 2 clinical trials. Clinical delays, safety concerns, or poor efficacy readouts for IMM-529 would severely damage the platform's credibility and depress the share price.

Base CaseCentral scenario

The base case assumes continued double-digit commercial sales growth for Travelan® in the US and Australia, alongside steady market penetration of ProIBS® in Australia and retail expansion in Canada. Clinical development of IMM-529 progresses into Phase 2 trials, and the company successfully initiates discussions with potential pharmaceutical partners to out-license or co-develop its lead assets, extending its cash runway beyond 2027 without excessive equity dilution.

Bull CaseUpside scenario

Strong commercial momentum of Travelan® in the US and Australia, combined with the successful launch of ProIBS® in Australia, provides a growing revenue base that offsets clinical development costs. Additionally, positive Phase 2 clinical trial results for lead candidates IMM-124E and IMM-529 could validate the proprietary polyclonal antibody platform and attract lucrative strategic licensing partnerships.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Versatile, validated platform technology utilizing hyperimmune bovine colostrum to generate highly specific oral polyclonal antibodies.
Established commercial revenue streams from Travelan® and ProIBS® that offset operational cash burn.
FDA IND approval for IMM-529, positioning the asset for Phase 2 clinical entry in a high-value, unmet medical need indication (C. difficile).
Strong balance sheet with AUD $10.0 million in cash as of December 31, 2025, providing a runway into 2027.

Key Investment Risks

High dependence on external capital or partnerships to fund late-stage clinical development.
Clinical trial execution risks, including patient recruitment delays and potential failure to demonstrate efficacy in large-scale human trials.
Dilution risk from the ongoing utilization of the company's At-The-Market (ATM) financing facility.
Key person risk and organizational constraints with a small internal team of approximately 7 employees.

Thesis Invalidation Triggers

Failure to secure a strategic development partner for IMM-529 or IMM-124E within the next 12-18 months.
Inability to initiate or complete the Phase 2 clinical trial for IMM-529 due to regulatory or operational hurdles.
A material decline in Travelan® commercial sales in key markets (US and Australia).
Severe equity dilution exceeding 30% over the next fiscal year without corresponding clinical milestones.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.